Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective

Table 1

Relative risk of fractures.

	Hip	Vertebral	NHNV	Source
Denosumab	0.38	0.36	0.84	Boonen et al. 2011 [9], McClung et al. 2012 [10]
Generic Alendronate	0.62	0.62	0.82	NICE Evidence Review 2008 [11]; Inderjeeth et al. 2009 [12]
Zoledronate	0.82	0.34	0.73	Boonen et al. 2010 [13]
Risedronate	0.85	0.56	0.80	McClung et al. 2001 [14]; Inderjeeth et al. 2009 [12]; NICE Evidence Review 2008 [11]
Ibandronate	1.00	0.51	1.00	NICE Evidence Review 2008 [11]
Teriparatide	0.25	0.35	0.47	NICE Evidence Review 2008 [11]

Where data are unavailable in the PMO elderly, the RRs are assumed to be similar to the overall PMO population.